Amylin posts smaller 2nd-qtr 2011 loss despite lower Byetta sales - Pharmaceutical and Biotechnology News - Pharma Letter
Links shared publicly online about this topic.
- 116total visits
Amylin posts smaller 2nd-qtr 2011 loss despite lower Byetta sales - Pharmaceutical and Biotechnology News - Pharma Letter
US biotech Amylin Pharmaceuticals (Nasdaq: AMLN) saw its shares all 4.9% to $12.65 after it reported financial results for the quarter ended June 30, 2011 showing that GAAP net loss was $31.4 million, or $0.22 per share, compared to $44.2 million, or $0.3
View full resource at thepharmaletter.com
Tags: Diabetes Type 2 Medication, Diabetes Medication, Pharma, Biotech, Byetta, News
Most Recently Shared on July 27, 2011 at 11:49 am By:
RT @ThePharmaLetter: Amylin posts smaller 2nd-qtr 2011 loss despite lower Byetta sales http://bit.ly/nPuMfU #pharma
Advertisement
